A parallel study of careHPV and Hybrid Capture 2 human papillomavirus DNA testing for cervical cancer screening in rural China

Journal of Virological Methods

Volumn 202, Issue , 2014, Pages 73-78

  Lin, Chun Qing ^a   Chen, Feng ^a   Liu, Bin ^a   Zhang, Yong Zhen ^b   Cui, Xiao Li ^c   Li, Ai Mei ^d   Zhang, Wen Hua ^a   Chen, Wen ^a   Chang, Irene ^e   Sivasubramaniam, Priya ^f   Zhu, Julie ^g   Qiao, You Lin ^a  

^a CANCER HOSPITAL   (China)

^b SHANXI CANCER HOSPITAL   (China)

^c LIAONING CANCER HOSPITAL AND INSTITUTE   (China)

^d Women and Children' Hospital of Qinxian County   (China)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g QIAGEN North America   (United States)

Author keywords

CareHPV; Cervical cancer; Human papillomavirus (HPV); Hybrid Capture 2 (HC2)

Indexed keywords

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER SCREENING; CHINA; CULTURE MEDIUM; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PARALLEL DESIGN; PREDICTIVE VALUE; PRIORITY JOURNAL; RURAL AREA; SENSITIVITY AND SPECIFICITY; SPECIMEN TRANSPORT MEDIUM; TEST COLLECTION MEDIUM; UTERINE CERVIX CANCER; WART VIRUS; COMPARATIVE STUDY; EARLY DIAGNOSIS; EVALUATION STUDY; ISOLATION AND PURIFICATION; MIDDLE AGED; MOLECULAR DIAGNOSIS; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; RURAL POPULATION; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADULT; CHINA; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RURAL POPULATION; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

EID: 84897041650     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2014.03.002     Document Type: Article

References (23)

1. Carozzi F.M., Del Mistro A., Confortini M., Sani C., Puliti D., Trevisan R., De Marco L., Tos A.G., Girlando S., Palma P.D., Pellegrini A., Schiboni M.L., Crucitti P., Pierotti P., Vignato A., Ronco G. Reproducibility of HPV DNA testing by Hybrid Capture 2 in a screening setting. Am. J. Clin. Pathol. 2005, 124:716-721.
2. Castle P.E., Schiffman M., Burk R.D., Wacholder S., Hildesheim A., Herrero R., Bratti M.C., Sherman M.E., Lorincz A. Restricted cross-reactivity of Hybrid Capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol. Biomarkers Prev. 2002, 11:1394-1399.
3. Castle P.E., Wheeler C.M., Solomon D., Schiffman M., Peyton C.L. Interlaboratory reliability of Hybrid Capture 2. Am. J. Clin. Pathol. 2004, 122:238-245.
4. Cuzick J., Arbyn M., Sankaranarayanan R., Tsu V., Ronco G., Mayrand M.H., Dillner J., Meijer C.J. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008, 26(Suppl. 10):K29L 41.
5. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 2010, International Agency for Research on Cancer, Lyon, France, Available from: http://globocan.iarc.fr (accessed 01.11.13).
6. Gage J.C., Ajenifuja K.O., Wentzensen N., Adepiti A.C., Stoler M., Eder P.S., Bell L., Shrestha N., Eklund C., Reilly M., Hutchinson M., Wacholder S., Castle P.E., Burk R.D., Schiffman M. Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria. Int. J. Cancer 2012, 131:2903-2909.
7. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., Tang G.W., Ferris D.G., Steben M., Bryan J., Taddeo F.J., Railkar R., Esser M.T., Sings H.L., Nelson M., Boslego J., Sattler C., Barr E., Koutsky L.A. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 2007, 356:1928-1943.
8. Goldie S.J., Gaffikin L., Goldhaber-Fiebert J.D., Gordillo-Tobar A., Levin C., Mahe C., Wright T.C. Cost-effectiveness of cervical-cancer screening in five developing countries. N. Engl. J. Med. 2005, 353:2158-2168.
9. Gravitt P.E., Coutlee F., Iftner T., Sellors J.W., Quint W.G., Wheeler C.M. New technologies in cervical cancer screening. Vaccine 2008, 26(Suppl. 10):K42L 52.
10. International Agency for Research on Cancer Chapter 2: screening tests. IARC Handbooks of Cancer Prevention: Cervix Cancer Screening 2005, vol. 10:59-115. IARC Press, Lyon.
11. Lorincz A.T. Hybrid capture method for detection of human papillomavirus DNA in clinical specimens: a tool for clinical management of equivocal Pap smears and for population screening. J. Obstet. Gynaecol. Res. 1996, 22:629-636.
12. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D.L., Kitchener H.C., Castellsague X., de Carvalho N.S., Skinner S.R., Harper D.M., Hedrick J.A., Jaisamrarn U., Limson G.A., Dionne M., Quint W., Spiessens B., Peeters P., Struyf F., Wieting S.L., Lehtinen M.O., Dubin G. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369:2161-2170.
13. Qiao Y.L., Sellors J.W., Eder P.S., Bao Y.P., Lim J.M., Zhao F.H., Weigl B., Zhang W.H., Peck R.B., Li L., Chen F., Pan Q.J., Lorincz A.T. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol. 2008, 9:929-936.
14. Sankaranarayanan R., Esmy P.O., Rajkumar R., Muwonge R., Swaminathan R., Shanthakumari S., Fayette J.M., Cherian J. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007, 370:398-406.
15. Sankaranarayanan R., Nene B.M., Shastri S.S., Jayant K., Muwonge R., Budukh A.M., Hingmire S., Malvi S.G., Thorat R., Kothari A., Chinoy R., Kelkar R., Kane S., Desai S., Keskar V.R., Rajeshwarkar R., Panse N., Dinshaw K.A. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 2009, 360:1385-1394.
16. Schlecht N.F., Kulaga S., Robitaille J., Ferreira S., Santos M., Miyamura R.A., Duarte-Franco E., Rohan T.E., Ferenczy A., Villa L.L., Franco E.L. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001, 286:3106-3114.
17. Shi J.F., Canfell K., Lew J.B., Zhao F.H., Legood R., Ning Y., Simonella L., Ma L., Kang Y.J., Zhang Y.Z., Smith M.A., Chen J.F., Feng X.X., Qiao Y.L. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. BMC Cancer 2011, 11:239.
18. Trope L.A., Chumworathayi B., Blumenthal P.D. Preventing cervical cancer: stakeholder attitudes toward CareHPV-focused screening programs in Roi-et Province, Thailand. Int. J. Gynecol. Cancer 2009, 19:1432-1438.
19. Wright T.C., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am. J. Obstet. Gynecol. 2007, 197:346-355.
20. Wu E.Q., Liu B., Cui J.F., Chen W., Wang J.B., Lu L., Niyazi M., Zhao C., Ren S.D., Li C.Q., Gong X.Z., Smith J.S., Belinson J.L., Liaw K.L., Velicer C., Qiao Y.L. Prevalence of type-specific human papillomavirus and pap results in Chinese women: a multi-center, population-based cross-sectional study. Cancer Causes Control 2013, 24:795-803.
21. Zhao F.H., Lin M.J., Chen F., Hu S.Y., Zhang R., Belinson J.L., Sellors J.W., Franceschi S., Qiao Y.L., Castle P.E. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol. 2010, 11:1160-1171.
22. Zhao F.H., Tiggelaar S.M., Hu S.Y., Xu L.N., Hong Y., Niyazi M., Gao X.H., Ju L.R., Zhang L.Q., Feng X.X., Duan X.Z., Song X.L., Wang J., Yang Y., Li C.Q., Liu J.H., Liu J.H., Lu Y.B., Li L., Zhou Q., Liu J.F., Zhao N., Schmidt J.E., Qiao Y.L. A multi-center survey of age of sexual debut and sexual behavior in Chinese women: suggestions for optimal age of human papillomavirus vaccination in China. Cancer Epidemiol. 2012, 36:384-390.
23. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2002, 2:342-350.